Edwards Lifesciences Forecasts Strong Sales and Earnings Growth

Edwards Lifesciences Forecasts Strong Sales and Earnings Growth in
IRVINE, CA -- (Marketwire) -- 12/04/12 --   Edwards Lifesciences
Corporation (NYSE: EW) 

--  Projected 13 to 16 Percent Underlying Global Sales Growth
--  U.S. Launch Fuels Expected Global THV Sales of $710 to $790 Million
--  Reaffirms Sales and Earnings Guidance for 2012

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the
science of heart valves and hemodynamic monitoring, today will
provide investors with information on the initiatives expected to
result in strong double-digit sales and earnings growth in 2013.
During its annual investor conference at its headquarters in Irvine,
Calif., Edwards' management will also discuss the company's strategy
for long-term growth, technology pipeline, ongoing U.S. transcatheter
heart valve launch and financial goals for 2013. 
"We expect 2013 will be another very rewarding year for Edwards
Lifesciences as we deliver new life saving technologies to patients
around the world," said Michael A. Mussallem, chairman and CEO. "We
are investing aggressively to drive breakthrough innovations in heart
valve treatment and to build on our legacy as a trusted partner in
the care of critically ill patients.  
"We project strong underlying(1) sales growth fueled by the ongoing
launch of our SAPIEN transcatheter heart valve in the U.S. Global
sales of our market-expanding transcatheter valves are expected to
grow to between $710 million and $790 million in 2013."  
During the conference, Edwards' management will present the company's
financial goals for 2013, which include total underlying sales growth
of 13 to 16 percent, a gross profit margin of 74 to 76 percent,
diluted earnings per share growth of more than 25 percent and free
cash flow(2) of $300 million to $340 million, with all goals
excluding special items. "Our strong bottom line growth projection
includes the estimated impact of the medical device excise tax, as
well as investments to prepare for the launch of our SAPIEN XT
transcatheter heart valve in Japan. We also expect to continue our
investment in research and development at approximately 15 percent of
sales in 2013, which positions us well to serve many more patients
with our innovative technologies and generate significant growth for
years to come," said Mussallem. 
Among the specific topics to be discussed at today's event are: 

--  Transcatheter Heart Valves - Aided by the recent U.S. FDA approval of
    SAPIEN for the treatment of high-risk patients and also for
    transapical delivery, transcatheter valve sales in the U.S. are
    projected to be $390 million to $440 million in 2013, which will
    contribute to an estimated global underlying growth rate of 30 to 45
    U.S. clinical and regulatory progress on the Edwards SAPIEN XT
    transcatheter valve remains on track. Regulatory and reimbursement
    approvals in Japan for SAPIEN XT are expected by the end of 2013.
    Edwards is continuing to make progress with its two newest
    transcatheter valve platforms, Edwards SAPIEN 3 and Edwards CENTERA,
    which are designed to extend its leadership position in this rapidly
    growing field. By the end of 2013, the company expects to receive a CE
    Mark for the SAPIEN 3 valve, a lower profile balloon expandable valve
    designed to further reduce paravalvular leak.
--  Surgical Heart Valve Therapy - Edwards is making substantial
    investments in new surgical valve technologies designed to extend its
    leadership and improve patient recovery and outcomes. In 2013, the
    company expects to initiate the European commercial launch of its
    innovative EDWARDS INTUITY valve system. Edwards is also planning to
    introduce a selection of unique tools designed to facilitate minimally
    invasive valve procedures.
    In early 2013, Edwards expects to initiate enrollment in the U.S.
    clinical study of GLX, its next-generation tissue technology, on a
    surgical heart valve. Edwards will also unveil its new Zeta
    next-generation surgical valve platform, designed to be a long-term
    solution for younger patients.
    Edwards expects to generate Surgical Heart Valve Therapy sales of
    $800 million to $840 million in 2013, representing a 4 to 6 percent
    underlying growth rate.
--  Critical Care - Building upon its global leadership in hemodynamic
    monitoring systems, Edwards expects growth across this product line
    driven primarily by the company's advanced monitoring technologies. At
    the conference, Edwards will be highlighting two important new
    technologies expected to improve the care of critically ill patients
    beginning in 2013. These technologies include the recent addition of a
    non-invasive monitoring platform and the GlucoClear hospital glucose
    monitoring system.
    Critical Care sales are projected to be $560 million to $600 million
    for 2013, representing 4 to 6 percent underlying growth.
--  Financial Outlook - Edwards will reaffirm its 2012 sales and earnings
    guidance, which includes diluted earnings per share of $2.54 to $2.58,
    excluding special items. The company will also detail its expectations
    for 2013, including total sales of $2.1 billion to $2.2 billion.
    Excluding special items, Edwards expects 2013 diluted earnings per
    share of $3.21 to $3.31, an increase of more than 25 percent over
    projected 2012 earnings.

In addition to Mr. Mussallem, other members of Edwards' management team
presenting at the conference include: 
Thomas M. Abate, corporate vice president and chief financial
 Donald E. Bobo, Jr., corporate vice president, Heart Valve
 Carlyn D. Solomon, corporate vice president, Critical Care
and Vascular; and
 Larry L. Wood, corporate vice president,
Transcatheter Valve Replacement. 
Guest Speakers to Provide Clinical Perspective  
Also speaking at the conference are interventional cardiologist John
G. Webb, MD, Director of Interventional Cardiology and Cardiac
Catheterization Laboratories at St. Paul's Hospital, Vancouver, and
cardiothoracic surgeon Robert Saeid Farivar, MD, PhD, Chief of
Cardiovascular Surgery at Pennsylvania Hospital, University of
Pennsylvania, Philadelphia, who will discuss their perspectives on
heart valve therapies.  
Webcast Information  
The Edwards Lifesciences 2012 Investor Conference can be accessed via
live webcast at http://ir.edwards.com/investor-conference.cfm
beginning at 8:00 a.m. Pacific Time on December 4, 2012. The webcast
will also be archived on the Edwards Web site after the conference
About Edwards Lifesciences  
Edwards Lifesciences is the global leader in the science of heart
valves and hemodynamic monitoring. Driven by a passion to help
patients, the company partners with clinicians to develop innovative
technologies in the areas of structural heart disease and critical
care monitoring that enable them to save and enhance lives.
Additional company information can be found at www.edwards.com.  
This news release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. These forward-looking
statements can sometimes be identified by the use of words such as
"may," "will," "should," "anticipate," "believe," "plan," "project,"
"estimate," "expect," "intend," "guidance," "outlook," "optimistic,"
"aspire," "confident" or other forms of these words or similar
expressions and may include, but are not limited to, Mr. Mussallem's
statements; the Company's 2012 and 2013 financial goals or
expectations for sales and sales growth, gross profit margin, net
income and net income growth, earnings per share and earnings per
share growth, R&D expense, free cash flow and other financial
expectations; strategies for long-term growth; and expectations
regarding the development and introduction of new products,
indications and technologies (including expected timelines and
outcomes of clinical trials, regulatory approvals, reimbursement and
market opportunities). Forward-looking statements are based on
estimates and assumptions made by management of the Company and are
believed to be reasonable, though they are inherently uncertain and
difficult to predict. Our forward-looking statements speak only as of
the date on which they are made and we do not undertake any
obligation to update any forward-looking statement to reflect events
or circumstances after the date of the statement. If the Company does
update or correct one or more of these statements, investors and
others should not conclude that the Company will make additional
updates or corrections. 
Forward-looking statements involve risks and uncertainties that could
cause actual results or experience to differ materially from that
expressed or implied by the forward-looking statements. Factors that
could cause actual results or experience to differ materially from
that expressed or implied by the forward-looking statements include
the unexpected changes or developments in opportunities for the
Company's transcatheter valve programs and the ability of the Company
to continue to lead in the development of this field; the Company's
success in developing new products, obtaining regulatory approvals,
and creating new market opportunities for its products; quality or
manufacturing issues; the availability and levels of reimbursement
for the Company's products; the impact of competitive products;
changes in currency exchange rates; unexpected changes to the timing
or results of pending or future clinical trials; actions by the U.S.
Food and Drug Administration and other regulatory agencies; and other
risks detailed in the Company's filings with the Securities and
Exchange Commission including its Annual Report on Form 10-K for the
year ended December 31, 2011.  
To supplement the consolidated financial results prepared in
accordance with Generally Accepted Accounting Principles ("GAAP"),
the Company uses non-GAAP financial measures. The Company uses the
term "underlying" when referring to non-GAAP sales information, which
excludes discontinued and acquired products and foreign exchange
fluctuations, and "excluding special items" to also exclude gains and
losses from special items such as significant investments,
litigation, and business development transactions. Guidance for sales
and sales growth rates is provided on an "underlying" basis, and
projections for diluted earnings per share, gross profit margin, net
income and growth, and free cash flow are also provided on the same
non-GAAP (or "excluding special items") basis due to the inherent
difficulty in forecasting such items. Management does not consider
the excluded items part of day-to-day business or reflective of the
core operational activities of the Company as they result from
transactions outside the ordinary course of business. Management uses
non-GAAP financial measures internally for strategic decision making,
forecasting future results and evaluating current performance. By
disclosing non-GAAP financial measures, management intends to provide
investors with a more meaningful, consistent comparison of the
Company's core operating results and trends for the periods
presented. These non-GAAP financial measures are used in addition to
and in conjunction with results presented in accordance with GAAP and
reflect an additional way of viewing aspects of the company's
operations that, when viewed with its GAAP results, provide a more
complete understanding of factors and trends affecting the company's
business. These non-GAAP measures should be considered as a
supplement to, and not as a substitute for, or superior to, the
corresponding measures calculated in accordance with generally
accepted accounting principles. Non-GAAP financial measures are not
prepared in accordance with GAAP; therefore, the information is not
necessarily comparable to other companies. The Company is not able to
provide a reconciliation of projections for underlying sales and
sales growth or projected gross profit margin, net income and growth,
projected earnings per share guidance and projected free cash flow,
excluding special items, to expected reported results due to the
unknown effect, timing and potential significance of special charges
or gains, and management's inability to forecast foreign currency
changes and charges associated with future transactions and
Edwards, Edwards Lifesciences, the stylized E logo, CENTERA, Edwards
GlucoClear, and GLX are trademarks of Edwards Lifesciences
(1) "Underlying" amounts are non-GAAP and in this press release
assumes a constant foreign currency rate in 2012 and 2013. 
(2) Free cash flow is defined as cash flow from operating activities
less capital expenditures. 
Media Contact:  
Sarah Huoh
Investor Contact:  
David K. Erickson
Edwards Lifesciences Corporation
One Edwards Way 
Irvine, CA USA 92614 
Phone: 949.250.2500 
Fax: 949.250.2525
Press spacebar to pause and continue. Press esc to stop.